Member Info for Moneymunch

Lovely indeed Porter, the conference starts tomorrow and so it would be amazing to get news on Monday, although regardless, I'm still sure June will see a significant re-rate as important news is delivered. Gl :')

"presentation of cutting-edge and unpublished research"

Maybe incoming news at next weeks conference from Vera's SIRT6 studies at University of Rochester. Gla ;-)

Systems Modeling, Aging Biomarkers, and Longevity Interventions

Systems Aging Gordon Research Conference

June 2 - 7, 2024

The Systems Aging GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages.

Keynote Session: Molecular Approaches in Age Reversal Research

Discussion Leader: Vera Gorbunova (University of Rochester, United States)

hTtps://www.grc.org/systems-aging-conference/2024/

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,618 followers

1d

For the first time since 2020, US life expectancy has increased.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is dedicated to ensuring that #healthspan grows alongside lifespan. Our groundbreaking research surrounding #SIRT6 mutations could revolutionize how we age and ensure we live healthier for longer.

Learn more about our research: htTps://loom.ly/uh0pGy8

I reckon we're going to see a decent re-rate this coming month on the back of important news and so I'd be surprised at anything sub 3p going forward...Big players are accumulating for big things to come and every chance of US institutional investors awaiting in the wings...Genflow's prospects and potential suggest the journey from small cap to mid cap is well underway. Gla :-)

Same here Porter, will not be selling any for the foreseeable. Endless multi-bag potential for life changing returns as we progress to clinical trials next year, including early acquisition/ Major JV partner. Gl :-)

M & A on the rise. Gla:-)

Genetic Engineering & Biotechnology News

Merck to Acquire UK Biotech EyeBio for Up to $3B, Re-Entering Eye Drug Space

May 29, 2024

Merck & Co. has agreed to acquire EyeBiotech (EyeBio) for up to $3 billion, the companies said today, in a deal that will return the buyer to the eye drug development segment it vacated about a decade ago.

Based in London, EyeBio has developed a pipeline of clinical and preclinical candidates designed to prevent and treat vision loss associated with retinal vascular leakage. EyeBio’s lead candidate Restoret™ (EYE103) is a tetravalent, tri-specific antibody agonist of the Wingless-related integration site (Wnt) signaling pathway.

https://www.genengnews.com/topics/drug-discovery/merck-to-acquire-eyebio-for-up-to-3b-re-entering-eye-drug-space/

Yep, small time profit makers have pulled the sp back, but full steam ahead this coming month imho, as the big players continue to accumulate and positive material news is delivered . Gl :-)

Just the start of Genflow’s stellar UPside journey. Gla holders:-)

Sarcopenia, another area of Genflow’s pipeline that could be of huge interest to a Major Pharma JV partner. Gla :-)

27/5/24

hTtps://longevity.technology/news/immunis-inks-licensing-deal-with-toray-for-potential-sarcopenia-drug/

Revatis

772 followers

April 2024

Exciting News! Collaboration Alert at Revatis!🔬

We are delighted to announce the expansion of the collaboration between #Trince and #Revatis, marking a significant milestone in our journey. Together, we are proud to introduce the first photoporation platform in Wallonia, developed as part of the Mitosir project under the "BioWin-ATMP collaborative project."

The Mitosir project is dedicated to tackling muscular mitochondrial dysfunction seen in sarcopenia, a significant health issue. For this purpose, we have joined forces with #Genflow, a distinguished industrial partner known for their expertise and intellectual property in Sirtuin peptides, which are essential for mitochondrial function and anti-aging.

We're confident this collaboration will propel research in the realm of muscle health, and we're proud to work in tandem with ULB and the Uliege to explore the fundamental aspects of this critical topic.

Keep an eye out for more thrilling updates on this project! 💪💡

#stemcells #cellgenetherapy #MuscleHealth #Research #Innovation #Revatis #Trince #Genflow #ULB #Uliege #Rise #Photoporation #MitochondrialDysfunction #Sarcopenia #Biowin #wallonierelance

............

Didier Serteyn

Professor Liege University

1d

Latest Development: In our pursuit of advancing tissue engineering and extra cellular Vesicles (exosomes) production, we're working towards a significant milestone. While our goal of harvesting 1 billion muscle derived MSCs (#revatis) from a single muscle microbiopsy (10 mg) at P3 is ambitious, we're making progress step by step.

Stay tuned for updates on our journey! #stemcells #tissueengineering #regenerativemedicine #cellandgenetherapy #equinehealth #exosomes #extracellularvesicles

RNS Number : 3593Q

Genflow Biosciences PLC

30 May 2024

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

30 May 2024

Genflow Biosciences Plc

Receipt of Grant Funding

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce receipt of 50% of its substantial non-diluting and non-reimbursable research grant. The amount received totals €381,434 from the Government of Wallonia in Belgium's Advanced Therapy Medicinal Products (ATMPs).

Genflow, together with its partner Revatis SA, has launched a 3-year sarcopenia research program [see news release here]. The remaining funds from the grant will be disbursed over the next two years based on submitted invoices. The grant will be utilized as working capital to support the Sarcopenia project.

The Sarcopenia Project focuses on the development of muscle progenitor cells (MPCs) which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia. This innovative approach aims to address the underlying causes of sarcopenia and promote muscle regeneration. Muscle progenitor cells are a type of stem cell capable of differentiating into muscle cells, playing a crucial role in muscle repair and regeneration. In sarcopenic muscles, the activity and number of MPCs decline, leading to impaired muscle regeneration. By loading MPCs with the SIRT6 gene, Genflow aims to enhance the regenerative capacity of these cells and counteract the detrimental effects of aging on muscle tissue.

Dr. Eric Leire, CEO of Genflow commented: "Sarcopenia, the age-related loss of muscle mass and function, is a significant health issue affecting older adults worldwide. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our Sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness."

Ditto Porter, I reckon we're in for a big day tomorrow and every chance we'll be testing 4p, and potentially significantly more if any big news drops at 7am. Fingers crossed!!! Gl ;-)

Perfectly poised and primed!!! Gla :-)

And another one Porter. Gl :-)

Licensing agreement focuses on development of epigenetic reprogramming treatments for age-related eye and ear conditions.

Longevity biotech Turn Biotechnologies today announced it has signed an exclusive global licensing agreement with Korean pharma giant HanAll Biopharma. The collaboration aims to develop multiple epigenetic reprogramming treatments for age-related eye and ear conditions, with the deal for the first product said to have a potential value of more than $300 million.

https://longevity.technology/news/turn-bio-inks-300m-epigenetic-reprogramming-deal-with-hanall-biopharma/amp/

Another great day as the re-rate continues, with a couple of chunky 600k trades that looked like sells which tempered the rise, although quickly absorbed into the ever diminishing free float as the demand for shares continues. Looking forward to the rest of the week and continued UPward momentum as we await the next UPdate or two. Gla holders...On and UP!!! :-)

Given how hot the liver space is and how compelling Sirt6's importance and influence appears to be in aging/longevity and multiple disease targets and Genflow's planned Nash trials, then the following deal announced end of April, for this early stage UK Biotech could be a high possibility for Genflow and due diligence could be in progress judging by the share accumulation. Gla holders, Exciting times!!!:-)))

German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.

Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.

The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.

The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for translating genetic information into proteins — can extend the lifespan of transplanted livers.

“What we’re trying to do is give the liver a little nudge in the right direction to support it to regenerate,” said Quin Wills, chief scientific officer and co-founder of Ochre Bio. “What happens in a cirrhotic liver is [cells] don’t have that decision-making process any more to start dividing and restoring capacity. By changing certain ‘switches’, using these RNA therapies, we help them make those decisions again.”

Not this time Lile imho, last years spike to 5p plus was on hype with no solid material news thereafter, unlike now, whereby multiple newsflow is expected, cemented by the recent €2.89m non-dilutive grant and the £770k cash injection from the new institutional investor on board, with every chance US institutional investors could be in the frame, along with the high chance of a Major JV partner who wants to get in early before next year's trials. Genflow's cutting edge science and unique position in the longevity space , with Sirt6's apparent importance suggests we're on a one way trajectory from small cap to mid cap. Watch this space!!! Gla holders...On and UP!!! :-)

In Eric we trust....this is just the start of Genflow’s stellar UPside journey. Gla holders:')

Lol...this is far from a joke, but I am laughing out loud!!! :-)))

Genflow's cutting edge science and compelling nature of Sirt6 thought to be the most important and potent Gene associated with aging/longevity and multiple disease targets is going to attract significant interest and investment going forward, a Major JV partner at anytime....Very exciting times for all invested.....Gla holders..:-)